By combining molecular biomarkers (CST1 and GIMAP1-GIMAP5), clinical data, and CT characteristics, this tool offers a personalized risk stratification approach to guide decisions on surveillance, biopsy, or intervention, potentially minimizing unnecessary procedures and improving timely management of lung adenocarcinoma in pandemic contexts. This evidence concerns the gene GIMAP1 and lung adenocarcinoma.